<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The der(1;7)(q10;p10) aberration is observed in about 1-3% of the <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and less commonly in <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) and the <z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>This unbalanced translocation is considered a "variant" of the del(7q)/-7 subgroup and has been assigned a poor risk karyotype score in the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> International Prognostic Scoring System (IPSS) </plain></SENT>
<SENT sid="2" pm="."><plain>Recent reports suggest der(1;7) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> should be considered a discrete <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> subgroup with an intermediate, not poor, karyotype score </plain></SENT>
<SENT sid="3" pm="."><plain>At the City of Hope, we compared the clinical-pathologic features of 12 der(1;7) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients to 51 MDS patients with del(7q) (n=10) or -7 (n=41), selected for a similar frequency of secondary aberrations </plain></SENT>
<SENT sid="4" pm="."><plain>The der(1;7) patients showed older age at diagnosis, lower platelet counts, less trilineage <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, and lower blast counts </plain></SENT>
<SENT sid="5" pm="."><plain>The der(1;7) patients did not differ from del(7q)/-7 patients in subtypes of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> by World Health Organization, French-American-British classifications, or bone marrow cellularity </plain></SENT>
<SENT sid="6" pm="."><plain>Neither the proportion of <z:e sem="disease" ids="C1292780" disease_type="Neoplastic Process" abbrv="">therapy-related MDS</z:e> nor the transformation to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> differed significantly among the three subgroups </plain></SENT>
<SENT sid="7" pm="."><plain>Five-year survival rates for der(1;7), del(7q), and -7 (44.4, 32.0, and 23.6%, respectively) did not differ significantly (P=0.94) </plain></SENT>
<SENT sid="8" pm="."><plain>While der(1;7) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> is associated with some clinically distinctive features, reassignment of risk category based on these data would be premature </plain></SENT>
</text></document>